Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

Cited by (1,002)

Items 301–400 of 1,002

1. Infection after CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: real-world analysis from CIBMTR
   Kitsada Wudhikarn, Megan M. Herr, Min Chen, Michael J. Martens, John H. Baird, Lohith Gowda, Hemalatha G. Rangarajan, Muhammad Bilal Abid, Mohamed A. Kharfan‐Dabaja, Kirsten M. Williams et al. · 2025 · Blood Advances
2. Longitudinal Collection of Patient-Reported Outcomes and Activity Data during CAR-T Therapy: Feasibility, Acceptability, and Data Visualization
   Laura B. Oswald, Xiaoyin Li, Rodrigo Carvajal, Aasha I. Hoogland, Lisa Marie Gudenkauf, Doris K. Hansen, Melissa Alsina, Frederick Lundry Locke, Yvelise Rodriguez, Nathaly E Irizarry-Arroyo et al. · 2022 · Cancers
3. Recent advances and clinical pharmacology aspects of Chimeric Antigen Receptor (CAR) T‐cellular therapy development
   Johannes Kast, Saeideh Nozohouri, Di Zhou, Marc R. Yago, Po‐Wei Chen, Malidi Ahamadi, Sandeep Dutta, Vijay V. Upreti · 2022 · Clinical and Translational Science
4. Natural killer cells: the next wave in cancer immunotherapy
   Xin Chen, Lei Jiang, Xuesong Liu · 2022 · Frontiers in Immunology
5. Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome
   Shakthi Bhaskar, Vivek G. Patel, David L. Porter, Stephen J. Schuster, Loretta J. Nastoupil, Miguel‐Angel Perales, Ana Alarcón Tomás, Michael Russell Bishop, Joseph P. McGuirk, Richard Thomas Maziarz et al. · 2022 · Blood Advances
6. The Dutch CAR-T Tumorboard Experience: Population-Based Real-World Data on Patients with Relapsed or Refractory Large B-Cell Lymphoma Referred for CD19-Directed CAR T-Cell Therapy in The Netherlands
   Anne Mea Spanjaart, Elise R. A. Pennings, Pim G. N. J. Mutsaers, Suzanne van Dorp, Margot Jak, Jaap A. van Doesum, Janneke de Boer, Anne G.H. Niezink, Milan Kos, Joost S.P. Vermaat et al. · 2023 · Cancers
7. The future of immunotherapy for diffuse large B‐cell lymphoma
   Johannes Duell, Jason R. Westin · 2024 · International Journal of Cancer
8. Recent advancement in targeted therapy and role of emerging technologies to treat cancer
   Shrikant Barot, Henis J. Patel, Anjali Yadav, Igor Ban · 2023 · Medical Oncology
9. Patterns of neurotoxicity among patients receiving chimeric antigen receptor T‐cell therapy: A single‐centre cohort study
   Carmela Sales, Mary Ann Anderson, Valeriya Kuznetsova, Hannah Rosenfeld, Charles Benjamin Malpas, Izanne Roos, Michael John Dickinson, Simon James Harrison, Tomáš Kalinčík · 2023 · European Journal of Neurology
10. Stealth transgenes enable CAR-T cells to evade host immune responses
    Korneel Grauwet, Trisha R. Berger, Michael C. Kann, Harrison Silva, Rebecca C. Larson, Mark B. Leick, Stefanie R. Bailey, Amanda A. Bouffard, David G. Millar, Kathleen Gallagher et al. · 2024 · Journal for ImmunoTherapy of Cancer
11. Real-world experience of commercial relmacabtagene autoleucel (relma-cel) for relapsed/refractory central nervous system lymphoma: a multicenter retrospective analysis of patients in China
    Wenyan Yu, Liang Huang, Heng Mei, Yuhua Li, Ting Niu, Dehui Zou, Yao Z. Liu, Huilai Zhang, Peng Liu, Jianqiu Wu et al. · 2024 · Journal for ImmunoTherapy of Cancer
12. Sequencing of cellular therapy and bispecific antibodies for the management of diffuse large B-cell lymphoma
    Megan Melody, Leo I. Gordon · 2024 · Haematologica
13. The high-grade B-cell lymphomas: double hit and more
    Andrew John Davies · 2024 · Blood
14. Lisocabtagene maraleucel for R/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study
    Alison R. Sehgal, Daanish Hoda, Peter A. Riedell, Nilanjan Ghosh, Mehdi Hamadani, Gerhard Carl Hildebrandt, John E. Godwin, Patrick Michael Reagan, Nina D. Wagner‐Johnston, James H. Essell et al. · 2025 · Blood Advances
15. Clinical presentation, management, and outcome of TIAN in CNS lymphoma treated with CD19-CAR T-cell therapy
    Leon D. Kaulen, Maria Martinez‐Lage, Jeremy S. Abramson, Philipp Karschnia, Sofia Doubrovinskaia, Ganesh M. Shankar, Bryan D. Choi, Christopher Michael Ramundo, Felix Ehret, Jeffrey A. Barnes et al. · 2025 · Blood
16. Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma
    Swetha Kambhampati, Monica Saumoy, Yecheskel Schneider, Stacy Pak, Lihua Elizabeth Budde, Matthew Genyeh Mei, Tanya Siddiqi, Leslie L. Popplewell, Yi-Ping Wen, Jasmine M. Zain et al. · 2022 · Blood
17. Long‐term survivorship care after CAR‐T cell therapy
    R. Puckrin, K. Jamani, V. Jimenez-Zepeda · 2023 · European Journal of Haematology
18. Metabolic parameters predict survival and toxicity in chimeric antigen receptor T‐cell therapy‐treated relapsed/refractory large B‐cell lymphoma
    Hazim Ababneh, Andrea K. Ng, Jeremy S. Abramson, Jacob Drobnyk Soumerai, Ronald W. Takvorian, Matthew J. Frigault, Chirayu G. Patel · 2023 · Hematological Oncology
19. Translational development of a novel BAFF-R CAR-T therapy targeting B-cell lymphoid malignancies
    Yan Luo, Yaqing Qie, Martha E. Gadd, Alak Manna, Rocio Krystal Rivera-Valentin, Tommy To, Shuhua Li, Farah Yassine, Hemant S. Murthy, Roxana Stefania Dronca et al. · 2023 · Cancer Immunology Immunotherapy
20. Insights gained from single-cell analysis of chimeric antigen receptor T-cell immunotherapy in cancer
    Lu Tang, Zhongpei Huang, Heng Mei, Yu Hu · 2023 · Military Medical Research
21. Estimation of eligibility for and response to CAR-T therapy in the United States
    Alyson Haslam, Tracy Beth Høeg, Vinay K. Prasad · 2023 · Blood Advances
22. Answering the “Doctor, can CAR-T therapy cause cancer?” question in clinic
    Rahul Kumar Banerjee, Christina Poh, Alexandre V. Vinaud Hirayama, Jordan Gauthier, Ryan Daniel Cassaday, Mazyar S. Shadman, Andrew J. Cowan, Brian G. Till, Damian J. Green, Hans‐Peter Kiem et al. · 2024 · Blood Advances
23. An updated cost-effectiveness analysis of axicabtagene ciloleucel in second-line large B-cell lymphoma patients in the United States
    Olalekan O. Oluwole, Anik R. Patel, Sachin Vadgama, Nathaniel Smith, Rob S. Blissett, Chaoling Feng, Michael John Dickinson, Patrick B. Johnston, Miguel‐Angel Perales · 2023 · Journal of Medical Economics
24. Cardiovascular toxicities associated with novel cellular immune therapies
    Malak Munir, Ahmed Sayed, Daniel Addison, Narendranath Epperla · 2024 · Blood Advances
25. Non-relapse mortality with bispecific antibodies: A systematic review and meta-analysis in lymphoma and multiple myeloma
    Tobias Tix, Mohammad Alhomoud, Roni Shouval, Gloria Iacoboni, Edward R. Scheffer Cliff, Doris K. Hansen, Saad Z. Usmani, Gilles A. Salles, Miguel‐Angel Perales, David M. Cordas dos Santos et al. · 2025 · Molecular Therapy
26. Myeloid neoplasms after CD19-directed CAR T cells therapy in long-term B-cell lymphoma responders, a rising risk over time?
    Nicolas Gazeau, D. Beauvais, R. Tilmont, M. Srour, E. Ferrant, V. Safar, L. Fouillet, P. Flandrin-Gresta, N. Gower, P. Chauvet et al. · 2025 · Leukemia
27. Chimeric Antigen Receptor T Cell Therapy versus Hematopoietic Stem Cell Transplantation: An Evolving Perspective
    Scott Ryan Goldsmith, Armin Ghobadi, John F. DiPersio, Brian Thomas Hill, Mayzar Shadman, Tania Jain · 2022 · Transplantation and Cellular Therapy
28. Migratory Engineering of T Cells for Cancer Therapy
    Stefanos Michaelides, Hannah Obeck, Daryna Kechur, Stefan Endres, Sebastian Kobold · 2022 · Vaccines
29. The race is on: bispecifics vs CAR T cells in B-cell lymphoma
    Ashwath Gurumurthi, Jason R. Westin, Marion Subklewe · 2023 · Blood Advances
30. Long-Term Survivors after Failure of Chimeric Antigen Receptor T Cell Therapy for Large B Cell Lymphoma: A Role for Allogeneic Hematopoietic Cell Transplantation? A German Lymphoma Alliance and German Registry for Stem Cell Transplantation Analysis
    Patrick Derigs, Wolfgang Andreas Bethge, Isabelle Krämer, Udo Holtick, Bastian von Tresckow, Francis Ayuketang Ayuk, Olaf Penack, Vladan Vučinić, Malte v. Bonin, Claudia Dorothea Baldus et al. · 2023 · Transplantation and Cellular Therapy
31. Transient acute kidney injury after chimeric antigen receptor T-cell therapy in patients with hematological malignancies
    Juan Carlos León-Román, Gloria Iacoboni, Sheila Bermejo, Cecilia del Carmen Carpio, Mónica Bolufer, Clara García-Carro, Mario Andrés Sánchez-Salinas, Carla Alonso‐Martínez, Oriol Bestard, Pere Barba et al. · 2024 · Clinical Kidney Journal
32. How I treat older patients with relapsed/refractory diffuse large B-cell lymphoma
    Danielle S. Wallace, Kah Poh Loh, Carla Casulo · 2024 · Blood
33. Sequencing of Anti-CD19 Therapies in the Management of Diffuse Large B-Cell Lymphoma
    Joseph Cornelius Lownik, Jonathan Boiarsky, Ruemu Ejedafeta Birhiray, Akil Abid Merchant, Monica Mead · 2024 · Clinical Cancer Research
34. EBV ‐positive diffuse large B‐cell lymphoma, not otherwise specified: 2024 update on the diagnosis, risk‐stratification, and management
    Luis Malpica, Mario Luiz Marques-Piubelli, Brady Beltrán, Julio C. Chávez, Roberto N. Miranda, Jorge Julio Castillo · 2024 · American Journal of Hematology
35. Anti-CD19 CAR-T cell therapy in elderly patients: multicentric real-world experience from GETH-TC/GELTAMO.
    R. Bailén, G. Iacoboni, Javier Delgado, L. López-Corral, Rafael Hernani-Morales, V. Ortíz-Maldonado, M. Guerreiro, A. Caballero, María Luisa Guerra Domínguez, J. Sánchez-Pina et al. · 2024 · Transplantation and Cellular Therapy
36. Tumor Biology Hides Novel Therapeutic Approaches to Diffuse Large B-Cell Lymphoma: A Narrative Review
    Romana Masnikosa, Zorica Cvetković, David Pirić · 2024 · International Journal of Molecular Sciences
37. Evolving strategies for addressing CAR T-cell toxicities
    Alexander W. Rankin, Brynn B. Duncan, Cecily Allen, Sara K. Silbert, Nirali N. Shah · 2024 · Cancer and Metastasis Reviews
38. Matching-adjusted indirect comparison of axi-cel and liso-cel in relapsed or refractory large B-cell lymphoma
    Olalekan O. Oluwole, Jenny M. H. Chen, Keith Chan, Anik R. Patel, Jeroen Paul Jansen, Sam Keeping, Yan Zheng, Julia Thornton Snider, Frederick Lundry Locke · 2022 · Leukemia & lymphoma/Leukemia and lymphoma
39. Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation
    Reid W. Merryman, Robert Allyn Redd, Eleanor Taranto, Gulrayz Ahmed, Erin Jeter, Kristin M McHugh, Jennifer R. Brown, Jennifer Leigh Crombie, Matthew Steven Davids, David Christopher Fisher et al. · 2022 · Blood Advances
40. CAR T cell therapy: looking back and looking forward
    Marco L. Davila, Renier J. Brentjens · 2022 · Nature Cancer
41. Head and Neck Cancer Immunotherapy: Molecular Biological Aspects of Preclinical and Clinical Research
    Rajdeep Chakraborty, Charbel Darido, Fei Liu, Maciej Maselko, Shoba Ranganathan · 2023 · Cancers
42. 2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma
    Ping Li, Yang Liu, Yun Liang, Jian Bo, Sujun Gao, Yongxian Hu, Yu Hu, He Huang, Xiao‐Jun Huang, Hongmei Jing et al. · 2023 · Cancer Biology and Medicine
43. Management Considerations for Patients With Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma
    Cassandra Duarte, Manali Kirtikumar Kamdar · 2023 · American Society of Clinical Oncology Educational Book
44. Single-Cell RNA Analysis Reveals Cell-Intrinsic Functions of CAR T Cells Correlating with Response in a Phase II Study of Lymphoma Patients
    Tina Sarén, Mohanraj Ramachandran, Gustav Gammelgård, Tanja Lövgren, Claudio Mirabello, Åsa K. Björklund, Kristina I. Wikstrom, Jamileh Hashemi, Eva Freyhult, Håkan K. Ahlström et al. · 2023 · Clinical Cancer Research
45. Outcomes of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Large B-Cell Lymphoma (LBCL): A Single-Institution Experience
    Aaron Trando, Anna Ter‐Zakarian, Phillip Yeung, Aaron Michael Goodman, Ayad Hamdan, Michael P. Hurley, Ah‐Reum Jeong, Dimitrios Tzachanis · 2023 · Cancers
46. Incorporating radiation with anti‐CD19 chimeric antigen receptor T‐cell therapy for relapsed/refractory non‐Hodgkin lymphoma: A multicenter consensus approach
    Omran Saifi, Scott C. Lester, William G. Breen, William G. Rule, Yi Lin, N. Nora Bennani, Allison Claire Rosenthal, Javier L Munoz, Hemant S. Murthy, Mohamed A. Kharfan‐Dabaja et al. · 2023 · American Journal of Hematology
47. New Insights into First-Line Therapy in Diffuse Large B-Cell Lymphoma: Are We Improving Outcomes?
    Pau Abrisqueta · 2024 · Journal of Clinical Medicine
48. CD20-bispecific antibodies improve response to CD19-CAR T cells in lymphoma in vitro and CLL in vivo models
    Berit J. Brinkmann, Alessia Floerchinger, Christina Schniederjohann, Tobias Roider, Mariana Coelho, Norman L. Mack, Peter‐Martin Bruch, Nora Liebers, Sarah Dötsch, Dirk Hans Busch et al. · 2024 · Blood
49. Malnutrition and cachexia are associated with poor CAR T-cell therapy outcomes including survival
    Brittany Cucchiaro, Nathan A. Davies, Christine Elizabeth Weekes, Maeve A O'Reilly, Claire Roddie, Adrian Slee · 2024 · Clinical Nutrition ESPEN
50. Multiomic analysis identifies a high-risk signature that predicts early clinical failure in DLBCL
    Kerstin Wenzl, Matthew E. Stokes, Joseph P. Novak, Allison Marie Bock, Sana Khan, Melissa A. Hopper, Jordan Edward Krull, Abigail R. Dropik, Janek S. Walker, Vivekananda Sarangi et al. · 2024 · Blood Cancer Journal
51. Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment
    Gloria Iacoboni, Vı́ctor Navarro, Pierre Sesques, Kai Rejeski, Mariana Bastos‐Oreiro, Fabio Serpenti, Ana África Martín López, Josu Iraola‐Truchuelo, Javier Delgado, Ariadna Pérez et al. · 2024 · Journal of Hematology & Oncology
52. Comparative infection risk in CAR T vs bispecific antibodies in B-cell lymphoma: a systematic review and meta-analysis
    Herman J. van Besien, Neela Easwar, Michelle R. Demetres, Michelle S Pasciolla, Tsiporah B. Shore, John Paul Leonard, Juliet N. Barker, Peter Martin, Samuel Yamshon · 2025 · Blood Advances
53. Cytokine storm
    Rajendra Karki, Mihai Gheorghe Netea, Caroline Diorio, Thirumala‐Devi Kanneganti · 2026 · Nature Reviews Disease Primers
54. A vision for the future of allogeneic hematopoietic stem cell transplantation in the next decade
    Meng Lv, Norbert Claude Gorin, Xiao‐Jun Huang · 2022 · 中国科学通报：英文版
55. Sequencing therapy in relapsed DLBCL
    Christopher R. Flowers, Oreofe Olukemi Odejide · 2022 · Hematology
56. Clinical Impact of Single Nucleotide Polymorphism in CD-19 on Treatment Outcome in FMC63-CAR-T Cell Therapy
    Katja Seipel, Mariesol Abbühl, Ulrike Bacher, Henning Nilius, Michael Daskalakis, Thomas Pabst · 2023 · Cancers
57. Novel agents in relapsed/refractory diffuse large B‐cell lymphoma
    Gaurav Varma, Jordan Goldstein, Ranjana H. Advani · 2023 · Hematological Oncology
58. New treatment options in elderly patients with Diffuse Large B-cell Lymphoma
    Annalisa Arcari, Federica Cavallo, Benedetta Puccini, Daniele Vallisa · 2023 · Frontiers in Oncology
59. Radiation and Dose-densification of R-CHOP in Primary Mediastinal B-cell Lymphoma: Subgroup Analysis of the UNFOLDER Trial
    Gerhard Held, Lorenz Thurner, Viola Poeschel, German Ott, Christian Schmidt, Konstantinos Christofyllakis, Andreas Viardot, Peter Borchmann, Walburga Engel-Riedel, Norbert Frickhofen et al. · 2023 · HemaSphere
60. Public Attitudes About the Use of Gene Therapy in Mainland China
    Yiqi Li, Xinyue Zhang, Ze Xiang, Tianle Chen, Zihao Hu, Kexin Yang, Xinying Sun, Yibo Wu, Jian Wu · 2023 · JAMA Network Open
61. Development and characterization of NILK-2301, a novel CEACAM5xCD3 κλ bispecific antibody for immunotherapy of CEACAM5-expressing cancers
    A. Seckinger, Sara Majocchi, V. Moine, L. Nouveau, N. Hoang, B. Daubeuf, U. Ravn, Nicolas Plèche, Sébastien Calloud, Lucile Broyer et al. · 2023 · Journal of Hematology & Oncology
62. Chimeric Antigen Receptor (CAR)-T Cell Therapy for Non-Hodgkin’s Lymphoma
    Maria Florencia Giraudo, Zachary Jackson, Indrani Das, Olubukola M. Abiona, David N. Wald · 2024 · Pathogens and Immunity
63. Development and validation of an automated computational approach to grade immune effector cell-associated hematotoxicity
    Emily C. Liang, Kai Rejeski, Teng Fei, Aya A. Albittar, Jennifer Jing Huang, Andrew Jay Portuguese, Qian Vicky Wu, Sandeep S. Raj, Marion S. Subklewe, Roni Shouval et al. · 2024 · Bone Marrow Transplantation
64. CAR-T cell therapy: Efficacy in management of cancers, adverse effects, dose-limiting toxicities and long-term follow up.
    Mohamed Elmarasi, Islam Elkonaissi, A. Elsabagh, Engy Elsayed, Abdelrahman Elsayed, B. Elsayed, I. Elmakaty, Mohamed A. Yassin · 2024 · International Immunopharmacology
65. Automated Lugano Metabolic Response Assessment in 18 F-Fluorodeoxyglucose–Avid Non-Hodgkin Lymphoma With Deep Learning on 18 F-Fluorodeoxyglucose–Positron Emission Tomography
    Skander Jemaa, Souhila Ounadjela, Xiaoyong Wang, Tarec Christoffer El‐Galaly, Lale Kostakoglu, Andrea Knapp, Grace Ku, Lisa Musick, Denis Sahin, Michael C. Wei et al. · 2024 · Journal of Clinical Oncology
66. Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma
    Narendranath Epperla, Melanie Lucero, Tom Bailey, Laura Mirams, Jolenta Cheung, Mona Amet, Gary Milligan, Lei Chen · 2024 · Blood Cancer Journal
67. Safety and efficacy of amulirafusp alfa (IMM0306), a fusion protein of CD20 monoclonal antibody with the CD47 binding domain of SIRPα, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a phase 1/2 study
    Jianliang Yang, Yongping Song, Keshu Zhou, Zhiming Li, Mingzhi Zhang, Hongmei Jing, Zhen Wang, Yu Li, Wei Meng, Qiying Lu et al. · 2024 · Journal of Hematology & Oncology
68. Single-cell dynamics of breakthrough toxicities after anakinra prophylaxis for axicabtagene ciloleucel in lymphoma
    Matthew J. Frigault, Ning Yao, Trisha R. Berger, Marc Wehrli, Kathleen Gallagher, Nora Horick, Charlotte Graham, Caron Alyce Jacobson, Yi‐Bin Chen, Mark B. Leick et al. · 2025 · Blood Advances
69. Itacitinib for the prevention of IEC therapy–associated CRS: results from the 2-part phase 2 INCB 39110-211 study
    Matthew J. Frigault, Richard Thomas Maziarz, Jae H. Park, Aleksandr Lazaryan, Nirav Niranjan Shah, Jakub Svoboda, Lazaros J. Lekakis, Ran Reshef, Christine L. Phillips, Lea Micaletti Burke et al. · 2025 · Blood
70. Budget Impact Analysis of CAR T-cell Therapy for Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in Germany
    Daniela Skalt, Bernhard Mörtl, Michael von Bergwelt‐Baildon, Christian Schmidt, Wolfgang Schoel, Veit Bücklein, Tobias Weiglein, Martin H. Dreyling, Karin Berger · 2022 · HemaSphere
71. Distinct Genetically Determined Origins of Myd88 / BCL2 -Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
    Ruth Flümann, Julia Hansen, Benedikt W. Pelzer, Pascal Nieper, Tim Lohmann, Ilmars Kisis, Tobias Riët, Viktoria Kohlhas, Phuong‐Hien Nguyen, Martin Peifer et al. · 2022 · Blood Cancer Discovery
72. Diabetes insipidus and Guillain-Barré-like syndrome following CAR-T cell therapy: a case report
    Christian Koch, Juliane Fleischer, Todor A. Popov, Karl Frontzek, Bettina Schreiner, Patrick Roth, Markus Gabriel Manz, Simone Unseld, Antonia M. S. Müller, Norman F. Russkamp · 2023 · Journal for ImmunoTherapy of Cancer
73. Outcome Prediction in Patients With Large B-cell Lymphoma Undergoing Chimeric Antigen Receptor T-cell Therapy
    Conrad‐Amadeus Voltin, Philipp Gödel, Laura Beckmann, Jan‐Michel Heger, Carsten Kobe, Nadine Kutsch, Peter Borchmann, Markus Dietlein, Ken Herrmann, Matthias Stelljes et al. · 2023 · HemaSphere
74. Failure of CAR-T cell therapy in relapsed and refractory large cell lymphoma and multiple myeloma: An urgent unmet need.
    Yasmine St Martin, Joseph K. Franz, M. Agha, H. Lazarus · 2023 · Blood reviews
75. Consolidative radiotherapy for residual fluorodeoxyglucose activity on day +30 post CAR T-cell therapy in non-Hodgkin lymphoma
    Omran Saifi, William G. Breen, Scott C. Lester, William G. Rule, Bradley J. Stish, Allison Claire Rosenthal, Javier L Munoz, Yi Lin, Radhika Bansal, Matthew A. Hathcock et al. · 2023 · Haematologica
76. Radiation and Dose-densification of R-CHOP in Aggressive B-cell Lymphoma With Intermediate Prognosis: The UNFOLDER Study
    Lorenz Thurner, Marita Ziepert, Christian Berdel, Christian Schmidt, Peter Borchmann, Dominic Kaddu‐Mulindwa, Andreas Viardot, Mathias Witzens‐Harig, Judith Dierlamm, Mathias Haenel et al. · 2023 · HemaSphere
77. Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy
    Madiha Iqbal, Deepa Jagadeesh, Julio C. Chávez, Arushi Khurana, Allison Claire Rosenthal, Emily C. Craver, Narendranath Epperla, Zhuo Li, Iris Isufi, Farrukh Tauseef Awan et al. · 2023 · Bone Marrow Transplantation
78. Current Challenges in Chimeric Antigen Receptor T-cell Therapy in Patients With B-cell Lymphoid Malignancies
    Seok Jin Kim, Sang Eun Yoon, Won Seog Kim · 2024 · Annals of Laboratory Medicine
79. FDA Approval Summary: Lisocabtagene Maraleucel for Second-Line Treatment of Large B-Cell Lymphoma
    Mona Elmacken, Helkha Peredo-Pinto, Cong Wang, Zhenzhen Xu, Million A. Tegenge, Adnan A. Jaigirdar, Marc Robert Theoret, Tejashri Purohit-Sheth, Yvette L. Kasamon · 2024 · Clinical Cancer Research
80. What clinicians should know about surrogate end points in hematologic malignancies
    Côme Bommier, Matthew John Maurer, Jérôme Lambert · 2024 · Blood
81. Patient-Reported Outcomes in Phase 3 Clinical Trials for Blood Cancers: A Systematic Review
    Kishan Kamlesh Patel, Alexandra Ivanov, Tajmah Jocelyn, Andrew Hantel, Jacqueline Suen Garcia, Gregory Alan Abel · 2024 · JAMA Network Open
82. Bispecific antibodies for the treatment of hematologic malignancies: The magic is T-cell redirection
    Geoffrey Shouse · 2024 · Blood Reviews
83. The endogenous T cell landscape is reshaped by CAR-T cell therapy and predicts treatment response in multiple myeloma
    Julia Frede, Julia C Poller, Kayleen Shi, Hannah Stuart, Noori Sotudeh, Claire C. Havig, Klothilda Lim, Caroline R.M. Wiggers, Eugene Y. Cho, Tushara Vijaykumar et al. · 2025 · Leukemia
84. CAR T-cell therapy for mantle cell lymphoma with central nervous system relapse
    Khoan Vu, Matthew Joshua Frank · 2022 · Blood Advances
85. An Epidemiological Model to Estimate the Prevalence of Diffuse Large B-Cell Lymphoma in the United States
    Dai Chihara, Karissa Johnston, Talshyn Bolatova, Shelagh M. Szabo, Anupama Kalsekar, Alex Mutebi, Huiying Yang, Yangyang Liu, Dionna Attinson, Martin Hutchings · 2022 · Clinical Lymphoma Myeloma & Leukemia
86. Chimeric antigen receptor T cell therapy for cancer: clinical applications and practical considerations
    Joseph E. Maakaron, Marie Hu, Najla El Jurdi · 2022 · BMJ
87. The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma
    Omar Albanyan, Julio C. Chávez, Javier L Munoz · 2022 · Therapeutic Advances in Hematology
88. Surface TREM2 on circulating M-MDSCs as a novel prognostic factor for adults with treatment-naïve diffuse large B-cell lymphoma
    Hao‐Yuan Wang, Fu-Chen Yang, Ching‐Fen Yang, Yao‐Chung Liu, Po‐Shen Ko, Chien-Jung Li, Chun‐Kuang Tsai, Yi‐Lin Chung, Nien‐Jung Chen · 2023 · Experimental Hematology and Oncology
89. Cytotoxicity of CD19-CAR-NK92 cells is primarily mediated via perforin/granzyme pathway
    Jonas Althaus, Verena Nilius‐Eliliwi, Abdelouahid Maghnouj, Sascha Döring, Roland Schroers, Michael Hudecek, Stephan A. Hahn, Thomas Mika · 2023 · Cancer Immunology Immunotherapy
90. Clinical development of chimeric antigen receptor-T cell therapy for hematological malignancies
    Zhihuan Yang, Ying Wang · 2023 · Chinese Medical Journal
91. Current and potential roles of immuno-PET/-SPECT in CAR T-cell therapy
    Aditi Mulgaonkar, Durga Udayakumar, Yaxing Yang, Shelby Freedman Harris, Orhan K. Öz, Praveen Ramakrishnan Geethakumari, Xiankai Sun · 2023 · Frontiers in Medicine
92. Cell-Based Models of ‘Cytokine Release Syndrome’ Endorse CD40L and Granulocyte–Macrophage Colony-Stimulating Factor Knockout in Chimeric Antigen Receptor T Cells as Mitigation Strategy
    Ala Dibas, Manuel Rhiel, Vidisha Bhavesh Patel, Geoffroy Andrieux, Melanie Boerries, Tatjana I. Cornu, Jamal Alzubi, Toni Cathomen · 2023 · Cells
93. Clinical features of neurotoxicity after CD19 CAR T-cell therapy in mantle cell lymphoma
    Esther H. Nie, Yi‐Jiun Su, John H. Baird, Neha Agarwal, Sushma Bharadwaj, Wen‐Kai Weng, Melody M. Smith, Saurabh Dahiya, May Htwe Han, Jeffrey Dunn et al. · 2024 · Blood Advances
94. Managing Infection Complications in the Setting of Chimeric Antigen Receptor T cell (CAR-T) Therapy
    Nausheen Ahmed, Olalekan O. Oluwole, Zahra Mahmoudjafari, Nahid Suleman, Joseph P. McGuirk · 2024 · Clinical Hematology International
95. Mitigating time toxicity in lymphoma and multiple myeloma
    Mengyang Di, Christopher T. Su, Andrew J. Cowan, Ajay K. Gopal, Rahul Kumar Banerjee · 2024 · Leukemia & lymphoma/Leukemia and lymphoma
96. Advances in the understanding and therapeutic manipulation of cancer immune responsiveness: a Society for Immunotherapy of Cancer (SITC) review
    Alessandra Cesano, Ryan C. Augustin, Luigi Barrea, Davide Bedognetti, Tullia Carmela Bruno, Alberto Carturan, Christian Hammer, Winson S. Ho, Jakob Nikolas Kather, Tomas Kirchhoff et al. · 2025 · Journal for ImmunoTherapy of Cancer
97. Specific Targeting of Multiple Myeloma by Dual Split-signaling Chimeric Antigen Receptor T cells Directed against CD38 and CD138
    van der Schans, Jort J., Wang, Ziyu, van Arkel, Jennemiek, van Schaik, Thijs, Katsarou, Afroditi, Ruiter, Ruud, Baardemans, Thomas, Yuan, Huipin, de Bruijn, Joost, Zweegman, Sonja et al. · 2023 · Clinical Cancer Research
98. Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study
    Adrian G. Minson, Emma Verner, Pratyush Giri, Jason Butler, Wojciech Janowski, Chan Yoon Cheah, Sumita Ratnasingam, Shu Min Wong, Matthew Ku, Mark Hertzberg et al. · 2025 · Journal of Clinical Oncology
99. Delayed Hematologic Toxicities Following Axicabtagene Ciloleucel and Tisagenlecleucel CAR-T Cell Therapy: A Retrospective Analysis of Lymphocytopenia, Neutropenia, and Thrombocytopenia
    Carina Bona, Roberto Lozano · 2024 · Asian journal of Current Research in Clinical Cancer
100. Outcomes of Autologous Hematopoietic Cell Transplantation in Older Patients with Diffuse Large B-Cell Lymphoma
     Pashna N. Munshi, Yue Chen, Kwang Woo Ahn, Farrukh Tauseef Awan, Amanda F. Cashen, Geoffrey Shouse, Mazyar S. Shadman, Paul J. Shaughnessy, Joanna C. Zurko, Frederick Lundry Locke et al. · 2022 · Transplantation and Cellular Therapy